中性粒细胞与淋巴细胞比值与弥漫性大 B 细胞淋巴瘤感染和生存的关系。
Association Between the Neutrophil-to-Lymphocyte Ratio and Infection and Survival in Diffuse Large B Cell Lymphoma.
机构信息
Department of Nursing, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan, R.O.C.
Department of Nursing, Tzu-Chi University, Hualien, Taiwan, R.O.C.
出版信息
In Vivo. 2023 Mar-Apr;37(2):948-954. doi: 10.21873/invivo.13167.
Abstract
BACKGROUND/AIM: Infection is a common cause of morbidity and mortality in patients treated for diffuse large B-cell lymphoma (DLBCL). However, there is limited information on the impact and risk factors for infection among patients receiving rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisolone (R-CHOP).
PATIENTS AND METHODS
A retrospective study evaluating patients with DLBCL receiving R-CHOP and R-COP between 2004 and 2021 was conducted at a medical center. Hospital patients' records for the five-item modified frailty index (mFI-5), sarcopenia, blood-based inflammatory markers, and clinical outcomes were statistically analyzed.
RESULTS
Patients with frailty, sarcopenia, and high neutrophil-to-lymphocyte ratio (NLR) were associated with a higher risk of infections. The revised International Prognostic Index poor-risk group, high NLR, infections, and treatment modality were risk factors for shorter progression-free and overall survival.
CONCLUSION
Pre-treatment high NLR was a predictor of infection and survival outcome in DLBCL patients.
摘要
背景/目的：感染是接受弥漫性大 B 细胞淋巴瘤（DLBCL）治疗患者发病率和死亡率的常见原因。然而，对于接受利妥昔单抗、环磷酰胺、长春新碱、多柔比星和泼尼松（R-CHOP）治疗的患者，有关感染的影响和危险因素的信息有限。
患者和方法
在一家医疗中心进行了一项回顾性研究，评估了 2004 年至 2021 年间接受 R-CHOP 和 R-COP 治疗的 DLBCL 患者。对五项改良虚弱指数（mFI-5）、肌肉减少症、基于血液的炎症标志物和临床结果的住院患者记录进行了统计学分析。
结果
虚弱、肌肉减少症和高中性粒细胞与淋巴细胞比值（NLR）的患者感染风险更高。修订后的国际预后指数不良风险组、高 NLR、感染和治疗方式是无进展生存期和总生存期较短的危险因素。
结论
治疗前高 NLR 是 DLBCL 患者感染和生存结果的预测因素。
相似文献
1
Association Between the Neutrophil-to-Lymphocyte Ratio and Infection and Survival in Diffuse Large B Cell Lymphoma.中性粒细胞与淋巴细胞比值与弥漫性大 B 细胞淋巴瘤感染和生存的关系。
In Vivo. 2023 Mar-Apr;37(2):948-954. doi: 10.21873/invivo.13167.
2
Neutrophil to lymphocyte ratio improves prognostic prediction of International Prognostic Index for patients with diffuse large B-cell lymphoma treated with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone.中性粒细胞与淋巴细胞比值改善了接受利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松治疗的弥漫性大B细胞淋巴瘤患者国际预后指数的预后预测。
Leuk Lymphoma. 2015 Jul;56(7):2032-8. doi: 10.3109/10428194.2014.982642. Epub 2015 Jan 21.
3
Prognostic impact of sarcopenia in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.利妥昔单抗联合环磷酰胺、多柔比星、长春新碱和泼尼松治疗弥漫性大 B 细胞淋巴瘤患者中肌肉减少症的预后影响。
J Cachexia Sarcopenia Muscle. 2016 Dec;7(5):567-576. doi: 10.1002/jcsm.12115. Epub 2016 Apr 12.
4
Cardiotoxicity with rituximab, cyclophosphamide, non-pegylated liposomal doxorubicin, vincristine and prednisolone compared to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone in frontline treatment of patients with diffuse large B-cell lymphoma: A randomised phase-III study from the Austrian Cancer Drug Therapy Working Group [Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14).与利妥昔单抗、环磷酰胺、阿霉素、长春新碱和泼尼松龙相比，利妥昔单抗、环磷酰胺、非聚乙二醇化脂质体阿霉素、长春新碱和泼尼松龙在弥漫性大B细胞淋巴瘤患者一线治疗中的心脏毒性：奥地利癌症药物治疗工作组[Arbeitsgemeinschaft Medikamentöse Tumortherapie AGMT](NHL-14)的一项随机III期研究。
Eur J Cancer. 2016 May;58:112-21. doi: 10.1016/j.ejca.2016.02.004. Epub 2016 Mar 15.
5
Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial.在马拉维，利妥昔单抗治疗弥漫性大 B 细胞淋巴瘤患者的安全性和疗效：一项前瞻性、单臂、非随机 1/2 期临床试验。
Lancet Glob Health. 2021 Jul;9(7):e1008-e1016. doi: 10.1016/S2214-109X(21)00181-9. Epub 2021 May 19.
6
A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.一种使用NCCN-IPI和中性粒细胞与淋巴细胞比值的弥漫性大B细胞淋巴瘤新预后模型。
Tumori. 2018 Aug;104(4):292-299. doi: 10.5301/tj.5000694. Epub 2018 May 8.
7
[Comparison the efficacy and prognosis of different first-line treatment for elderly diffuse large B-cell lymphoma].[比较老年弥漫性大B细胞淋巴瘤不同一线治疗的疗效及预后]
Zhonghua Zhong Liu Za Zhi. 2020 Mar 23;42(3):234-241. doi: 10.3760/cma.j.cn112152-20190705-00413.
8
Diffuse large B-cell lymphoma with concurrent hepatitis B virus infection in the MabThera era: Unique clinical features and worse outcomes.美罗华时代合并乙型肝炎病毒感染的弥漫性大B细胞淋巴瘤：独特的临床特征及更差的预后
J Cancer Res Ther. 2018;14(Supplement):S248-S253. doi: 10.4103/0973-1482.187285.
9
The impact of the neutrophil:lymphocyte ratio in response and survival of patients with de novo diffuse large B-cell lymphoma.中性粒细胞与淋巴细胞比值对初发弥漫性大B细胞淋巴瘤患者缓解情况及生存的影响
Leuk Res. 2018 Apr;67:82-85. doi: 10.1016/j.leukres.2018.02.011. Epub 2018 Feb 19.
10
An inflammation-based cumulative prognostic score system in patients with diffuse large B cell lymphoma in rituximab era.利妥昔单抗时代弥漫性大 B 细胞淋巴瘤患者基于炎症的累积预后评分系统。
BMC Cancer. 2018 Jan 2;18(1):5. doi: 10.1186/s12885-017-3931-z.
引用本文的文献
1
Association between complete blood count-derived inflammatory biomarkers and renal failure: a cross-sectional study from NHANES 2007-2020.全血细胞计数衍生的炎症生物标志物与肾衰竭之间的关联：一项来自2007 - 2020年美国国家健康与营养检查调查（NHANES）的横断面研究。
BMJ Open. 2025 Sep 1;15(9):e103381. doi: 10.1136/bmjopen-2025-103381.
2
Systemic inflammation response index as a prognostic factor for patients with sepsis-associated acute kidney injury: a retrospective observational study.全身性炎症反应指数作为脓毒症相关急性肾损伤患者的预后因素：一项回顾性观察研究。
J Int Med Res. 2024 Mar;52(3):3000605241235758. doi: 10.1177/03000605241235758.
3
A Novel Inflammatory-Nutritional Prognostic Scoring System for Patients with Diffuse Large B Cell Lymphoma.一种用于弥漫性大B细胞淋巴瘤患者的新型炎症-营养预后评分系统。
J Inflamm Res. 2024 Jan 3;17:1-13. doi: 10.2147/JIR.S436392. eCollection 2024.
本文引用的文献
1
Frailty in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Receiving Curative-Intent Therapy: A Population-Based Study.初诊弥漫性大 B 细胞淋巴瘤接受根治性治疗患者的脆弱性：一项基于人群的研究。
J Natl Compr Canc Netw. 2022 Jun;20(6):635-642.e9. doi: 10.6004/jnccn.2022.7014.
2
Prognostic Value of Sarcopenia in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A Systematic Review and Meta-Analysis.R-CHOP方案治疗的弥漫性大B细胞淋巴瘤患者中肌肉减少症的预后价值：一项系统评价和荟萃分析
Front Nutr. 2022 Feb 25;9:816883. doi: 10.3389/fnut.2022.816883. eCollection 2022.
3
Pegfilgrastim Prophylaxis Is Effective in the Prevention of Febrile Neutropenia and Reduces Mortality in Patients Aged ≥ 75 Years with Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Cohort Study.培格非格司亭预防治疗可有效预防发热性中性粒细胞减少症，并降低 R-CHOP 治疗的年龄≥75 岁弥漫性大 B 细胞淋巴瘤患者的死亡率：一项前瞻性队列研究。
Cancer Res Treat. 2022 Oct;54(4):1268-1277. doi: 10.4143/crt.2021.1168. Epub 2021 Dec 30.
4
Peripheral blood neutrophil-to-lymphocyte ratio is associated with mortality across the spectrum of cardiogenic shock severity.外周血中性粒细胞与淋巴细胞比值与心源性休克严重程度范围内的死亡率相关。
J Crit Care. 2022 Apr;68:50-58. doi: 10.1016/j.jcrc.2021.12.005. Epub 2021 Dec 15.
5
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma.泊洛妥珠单抗联合化疗治疗未经治疗的弥漫性大 B 细胞淋巴瘤
N Engl J Med. 2022 Jan 27;386(4):351-363. doi: 10.1056/NEJMoa2115304. Epub 2021 Dec 14.
6
Prognostic Role of "Radiological" Sarcopenia in Lymphoma: A Systematic Review.“放射学上的”肌肉减少症在淋巴瘤中的预后作用：一项系统综述
Clin Lymphoma Myeloma Leuk. 2022 May;22(5):e340-e349. doi: 10.1016/j.clml.2021.11.006. Epub 2021 Nov 12.
7
Use of a 5-Item Modified Frailty Index for Risk Stratification in Patients Undergoing Breast Reconstruction.使用 5 项修正虚弱指数对接受乳房重建的患者进行风险分层。
Ann Plast Surg. 2021 Jun 1;86(6S Suppl 5):S615-S621. doi: 10.1097/SAP.0000000000002765.
8
Prognostic model based on the geriatric nutritional risk index and sarcopenia in patients with diffuse large B-cell lymphoma.基于老年营养风险指数和肌肉减少症的弥漫性大 B 细胞淋巴瘤患者的预后模型。
BMC Cancer. 2020 May 18;20(1):439. doi: 10.1186/s12885-020-06921-2.
9
Prognostic value of sarcopenia in survivors of hematological malignances undergoing a hematopoietic stem cell transplantation: a systematic review and meta-analysis.肌肉减少症对接受造血干细胞移植的血液系统恶性肿瘤幸存者的预后价值：一项系统评价和荟萃分析。
Support Care Cancer. 2020 Aug;28(8):3533-3542. doi: 10.1007/s00520-020-05359-3. Epub 2020 Feb 23.
10
The Prognostic Value of Blood-Based Biomarkers in Patients With Testicular Diffuse Large B-Cell Lymphoma.血液生物标志物在睾丸弥漫性大B细胞淋巴瘤患者中的预后价值
Front Oncol. 2019 Dec 10;9:1392. doi: 10.3389/fonc.2019.01392. eCollection 2019.
Zotero 插件